Prescribing issues in elderly individuals living with HIV

References

• Antiretroviral Therapy Cohort C. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017 Aug;4(8):e349–56. PubMed PMID: 28501495; PubMed Central PMCID: PMC5555438.
   PubMed Web of Science ®Google Scholar
• Gueler A, Moser A, Calmy A, et al. Life expectancy in HIV-positive persons in Switzerland: matched comparison with general population. Aids. 2017 Jan 28;31(3):427–436. PubMed PMID: 27831953; PubMed Central PMCID: PMC5302412.
   PubMed Web of Science ®Google Scholar
• Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One. 2013;8(12):e81355. PubMed PMID: 24367482; PubMed Central PMCID: PMC3867319.
   PubMed Web of Science ®Google Scholar
• Wandeler G, Johnson LF, Egger M. Trends in life expectancy of HIV-positive adults on antiretroviral therapy across the globe: comparisons with general population. Curr Opin HIV AIDS. 2016 Sep;11(5):492–500. PubMed PMID: 27254748; PubMed Central PMCID: PMC5055447.
   PubMed Web of Science ®Google Scholar
• Guaraldi G, Zona S, Brothers TD, et al. Aging with HIV vs. HIV seroconversion at older age: a diverse population with distinct comorbidity profiles. PLoS One. 2015;10(4):e0118531. PubMed PMID: 25874806; PubMed Central PMCID: PMC4395353.
   PubMed Web of Science ®Google Scholar
• Smit M, Brinkman K, Geerlings S, et al. Future challenges for clinical care of an ageing population infected with HIV: a modelling study. Lancet Infect Dis. 2015 Jul;15(7):810–818. PubMed PMID: 26070969; PubMed Central PMCID: PMC4528076.
   PubMed Web of Science ®Google Scholar
• Smit M, Cassidy R, Cozzi-Lepri A, et al. Projections of non-communicable disease and health care costs among HIV-positive persons in Italy and the U.S.A.: a modelling study. PLoS One. 2017;12(10):e0186638. PubMed PMID: 29059202; PubMed Central PMCID: PMC5653300.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Definition of an older or elderly person; [Cited 2019 Mar 23]. https://www.who.int/healthinfo/survey/ageingdefnolder/en/
   Google Scholar
• Mangoni AA, Jackson SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2004 Jan;57(1):6–14. PubMed PMID: 14678335; PubMed Central PMCID: PMC1884408.
   PubMed Web of Science ®Google Scholar
• Stader F, Siccardi M, Battegay M, et al. Repository describing an aging population to inform physiologically based pharmacokinetic models considering anatomical, physiological, and biological age-dependent changes. Clin Pharmacokinet. 2019 Apr;58(4):483–501. PubMed PMID: 30128967.
   PubMed Web of Science ®Google Scholar
• Polasek TM, Patel F, Jensen BP, et al. Predicted metabolic drug clearance with increasing adult age. Br J Clin Pharmacol. 2013 Apr;75(4):1019–1028. PubMed PMID: 22924488; PubMed Central PMCID: PMC3612720.
   PubMed Web of Science ®Google Scholar
• Calza L, Colangeli V, Magistrelli E, et al. Plasma trough concentrations of darunavir/ritonavir and raltegravir in older patients with HIV-1 infection. HIV Med. 2017 Aug;18(7):474–481. PubMed PMID: 28116848.
   PubMed Web of Science ®Google Scholar
• Crawford KW, Spritzler J, Kalayjian RC, et al. Age-related changes in plasma concentrations of the HIV protease inhibitor lopinavir. AIDS Res Hum Retroviruses. 2010 Jun;26(6):635–643. PubMed PMID: 20560793; PubMed Central PMCID: PMC2932550.
   PubMed Web of Science ®Google Scholar
• Winston A, Jose S, Gibbons S, et al. Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring. J Antimicrob Chemother. 2013 Jun;68(6):1354–1359. PubMed PMID: 23435690.
   PubMed Web of Science ®Google Scholar
• Dumond JB, Adams JL, Prince HM, et al. Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study. HIV Med. 2013 Aug;14(7):401–409. PubMed PMID: 23433482; PubMed Central PMCID: PMC3664258.
   PubMed Web of Science ®Google Scholar
• Elliot ER, Wang X, Singh S, et al. Increased dolutegravir peak concentrations in people living with human immunodeficiency virus aged 60 and over, and analysis of sleep quality and cognition. Clin Infect Dis. 2019 Jan 1;68(1):87–95. PubMed PMID: 29771285.
   PubMed Web of Science ®Google Scholar
• Wooten JM. Pharmacotherapy considerations in elderly adults. South Med J. 2012 Aug;105(8):437–445. PubMed PMID: 22864103.
   PubMed Web of Science ®Google Scholar
• Jansen PA, Brouwers JR. Clinical pharmacology in old persons. Scientifica (Cairo). 2012;2012: 723678. PubMed PMID: 24278735; PubMed Central PMCID: PMC3820465.
   PubMedGoogle Scholar
• Albrecht S, Ihmsen H, Hering W, et al. The effect of age on the pharmacokinetics and pharmacodynamics of midazolam. Clin Pharmacol Ther. 1999 Jun;65(6):630–639. PubMed PMID: 10391668.
   PubMed Web of Science ®Google Scholar
• American Geriatrics Society Beers Criteria® update expert panel. American geriatrics society 2019 updated AGS beers criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019 Apr;67(4):674–694.
   Web of Science ®Google Scholar
• O’Mahony D, O’Sullivan D, Byrne S, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 2. Age Ageing. 2015 Mar;44(2):213–218. PubMed PMID: 25324330; PubMed Central PMCID: PMC4339726.
   PubMed Web of Science ®Google Scholar
• Diem SJ, Ewing SK, Stone KL, et al. Use of non-benzodiazepine sedative hypnotics and risk of falls in older men. J Gerontol Geriatr Res. 2014 Jul 1;3(3):158. PubMed PMID: 25587493; PubMed Central PMCID: PMC4289612.
   PubMedGoogle Scholar
• Glass J, Lanctot KL, Herrmann N, et al. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. Bmj. 2005 Nov 19;331(7526):1169. PubMed PMID: 16284208; PubMed Central PMCID: PMC1285093.
   PubMed Web of Science ®Google Scholar
• Ruxton K, Woodman RJ, Mangoni AA. Drugs with anticholinergic effects and cognitive impairment, falls and all-cause mortality in older adults: a systematic review and meta-analysis. Br J Clin Pharmacol. 2015 Aug;80(2):209–220. PubMed PMID: 25735839; PubMed Central PMCID: PMC4541969.
   PubMed Web of Science ®Google Scholar
• Rubin LH, Radtke KK, Eum S, et al. Cognitive burden of common non-antiretroviral medications in HIV-infected women. J Acquir Immune Defic Syndr. 2018 Sep 1;79(1):83–91. PubMed PMID: 29781879; PubMed Central PMCID: PMC6092212.
   PubMed Web of Science ®Google Scholar
• Livio F, Rrustemi F, Moffa G, et al. Polypharmacy, drug-drug interactions and potentially inappropriate prescribing in elderly patients of the Swiss HIV Cohort Study. 19th International Workshop on Clinical Pharmacology of Antiviral Therapy; May 22–24; Baltimore; 2018.
   Google Scholar
• Kidney Disease: Improving Global Outcomes Hepatitis CWG. KDIGO 2018 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl. 2018 Oct;8(3):91–165. PubMed PMID: 30675443; PubMed Central PMCID: PMC6336217.
   Web of Science ®Google Scholar
• Raman M, Middleton RJ, Kalra PA, et al. Estimating renal function in old people: an in-depth review. Int Urol Nephrol. 2017 Nov;49(11):1979–1988. PubMed PMID: 28913589; PubMed Central PMCID: PMC5643354.
   PubMed Web of Science ®Google Scholar
• Vass M, Hendriksen C. Medication for older people–aspects of rational therapy from the general practitioner’s point of view. Z Gerontol Geriatr. 2005 Jun;38(3):190–195. PubMed PMID: 15965793.
   PubMed Web of Science ®Google Scholar
• Allavena C, Hanf M, Rey D, et al. Antiretroviral exposure and comorbidities in an aging HIV-infected population: the challenge of geriatric patients. PLoS One. 2018;13(9):e0203895. PubMed PMID: 30240419; PubMed Central PMCID: PMC6150468.
   PubMed Web of Science ®Google Scholar
• Hasse B, Ledergerber B, Furrer H, et al. Morbidity and aging in HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis. 2011 Dec;53(11):1130–1139. PubMed PMID: 21998280.
   PubMed Web of Science ®Google Scholar
• Cuzin L, Katlama C, Cotte L, et al. Ageing with HIV: do comorbidities and polymedication drive treatment optimization? HIV Med. 2017 Jul;18(6):395–401. PubMed PMID: 28858437.
   PubMed Web of Science ®Google Scholar
• Kendall CE, Wong J, Taljaard M, et al. A cross-sectional, population-based study measuring comorbidity among people living with HIV in Ontario. BMC Public Health. 2014 Feb 13;14:161. PubMed PMID: 24524286; PubMed Central PMCID: PMC3933292.
   PubMed Web of Science ®Google Scholar
• Kooij KW, Vogt L, Wit F, et al. Higher prevalence and faster progression of chronic kidney disease in human immunodeficiency virus-infected middle-aged individuals compared with human immunodeficiency virus-uninfected controls. J Infect Dis. 2017 Sep 15;216(6):622–631. PubMed PMID: 28934420.
   PubMed Web of Science ®Google Scholar
• Mahale P, Engels EA, Coghill AE, et al. Cancer risk in older persons living with human immunodeficiency virus infection in the United States. Clin Infect Dis. 2018 Jun 18;67(1):50–57. PubMed PMID: 29325033; PubMed Central PMCID: PMC6248478.
   PubMed Web of Science ®Google Scholar
• Paisible AL, Chang CC, So-Armah KA, et al. HIV infection, cardiovascular disease risk factor profile, and risk for acute myocardial infarction. J Acquir Immune Defic Syndr. 2015 Feb 1;68(2):209–216. PubMed PMID: 25588033; PubMed Central PMCID: PMC4441201.
   PubMed Web of Science ®Google Scholar
• Rasch MG, Helleberg M, Feldt-Rasmussen B, et al. Increased risk of dialysis and end-stage renal disease among HIV patients in Denmark compared with the background population. Nephrol Dial Transplant. 2014 Jun;29(6):1232–1238. PubMed PMID: 23975841.
   PubMed Web of Science ®Google Scholar
• Schouten J, Wit FW, Stolte IG, et al. Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study. Clin Infect Dis. 2014 Dec 15;59(12):1787–1797. PubMed PMID: 25182245.
   PubMed Web of Science ®Google Scholar
• Sico JJ, Chang CC, So-Armah K, et al. HIV status and the risk of ischemic stroke among men. Neurology. 2015 May 12;84(19):1933–1940. PubMed PMID: 25862803; PubMed Central PMCID: PMC4433456.
   PubMed Web of Science ®Google Scholar
• Silverberg MJ, Lau B, Achenbach CJ, et al. Cumulative incidence of cancer among persons with HIV in North America: a cohort study. Ann Intern Med. 2015 Oct 6;163(7):507–518. PubMed PMID: 26436616; PubMed Central PMCID: PMC4711936.
   PubMed Web of Science ®Google Scholar
• Tripathi A, Liese AD, Winniford MD, et al. Impact of clinical and therapeutic factors on incident cardiovascular and cerebrovascular events in a population-based cohort of HIV-infected and non-HIV-infected adults. Clin Cardiol. 2014 Sep;37(9):517–522. PubMed PMID: 25223811.
   PubMed Web of Science ®Google Scholar
• Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol. 2008 Jan;214(2):231–241. PubMed PMID: 18161758.
   PubMed Web of Science ®Google Scholar
• Sabin CA, Reiss P. Epidemiology of ageing with HIV: what can we learn from cohorts? Aids. 2017 Jun 1;31(Suppl 2):S121–8. PubMed PMID: 28471942.
   PubMed Web of Science ®Google Scholar
• Calza L, Colangeli V, Manfredi R, et al. Clinical management of dyslipidaemia associated with combination antiretroviral therapy in HIV-infected patients. J Antimicrob Chemother. 2016 Jun;71(6):1451–1465. PubMed PMID: 26846208.
   PubMed Web of Science ®Google Scholar
• European AIDS clinical society (EACS) guidelines. version 9.1; Oct 2018.
   Google Scholar
• Mocroft A, Lundgren JD, Ross M, et al. Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study. Lancet HIV. 2016 Jan;3(1):e23–32. PubMed PMID: 26762990.
   PubMed Web of Science ®Google Scholar
• Gnjidic D, Hilmer SN, Blyth FM, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol. 2012 Sep;65(9):989–995. PubMed PMID: 22742913.
   PubMed Web of Science ®Google Scholar
• Haefeli WE, Meid AD. Pill-count and the arithmetic of risk: evidence that polypharmacy is a health status marker rather than a predictive surrogate for the risk of adverse drug events. Int J Clin Pharmacol Ther. 2018 Dec;56(12):572–576. PubMed PMID: 30369395.
   PubMed Web of Science ®Google Scholar
• Lopez-Centeno B, Badenes-Olmedo C, Mataix-Sanjuan A, et al. Polypharmacy and drug-drug interactions in HIV-infected subjects in the region of Madrid (Spain): a population-based study. 14th International Congress on Drug Therapy in HIV Infection; October 28–31; Glasgow; 2018.
   Google Scholar
• Rasmussen LD, Kronborg G, Larsen CS, et al. Use of non-antiretroviral drugs among individuals with and without HIV-infection: a Danish nationwide study. Infect Dis (Lond). 2017 Jan;49(1):42–54. PubMed PMID: 27686116.
   PubMed Web of Science ®Google Scholar
• Guaraldi G, Malagoli A, Calcagno A, et al. The increasing burden and complexity of multi-morbidity and polypharmacy in geriatric HIV patients: a cross sectional study of people aged 65–74 years and more than 75 years. BMC Geriatr. 2018 Apr 20;18(1):99. PubMed PMID: 29678160; PubMed Central PMCID: PMC5910563.
   PubMed Web of Science ®Google Scholar
• Greene M, Steinman MA, McNicholl IR, et al. Polypharmacy, drug-drug interactions, and potentially inappropriate medications in older adults with human immunodeficiency virus infection. J Am Geriatr Soc. 2014 Mar;62(3):447–453. PubMed PMID: 24576251; PubMed Central PMCID: PMC4043391.
   PubMed Web of Science ®Google Scholar
• Holtzman C, Armon C, Tedaldi E, et al. Polypharmacy and risk of antiretroviral drug interactions among the aging HIV-infected population. J Gen Intern Med. 2013 Oct;28(10):1302–1310. PubMed PMID: 23605401; PubMed Central PMCID: PMC3785656.
   PubMed Web of Science ®Google Scholar
• Justice AC, Gordon KS, Skanderson M, et al. Nonantiretroviral polypharmacy and adverse health outcomes among HIV-infected and uninfected individuals. Aids. 2018 Mar 27;32(6):739–749. PubMed PMID: 29543653; PubMed Central PMCID: PMC5868488.
   PubMed Web of Science ®Google Scholar
• Krentz HB, Gill MJ. The impact of non-antiretroviral polypharmacy on the continuity of antiretroviral therapy (ART) among HIV patients. AIDS Patient Care STDS. 2016 Jan;30(1):11–17. PubMed PMID: 26544766.
   PubMed Web of Science ®Google Scholar
• McNicholl IR, Gandhi M, Hare CB, et al. A pharmacist-led program to evaluate and reduce polypharmacy and potentially inappropriate prescribing in older HIV-positive patients. Pharmacotherapy. 2017 Dec;37(12):1498–1506. PubMed PMID: 29023938.
   PubMed Web of Science ®Google Scholar
• Nunez-Nunez M, Castaneda-Macias I. Sandoval-Fernandez Del Castillo, S. Potential interactions in a cohort of elderly hiv-positive patients. Farm Hosp. 2018 Jul 1;42(4):163–167. PubMed PMID: 29959841.
   PubMed Web of Science ®Google Scholar
• Ssonko M, Stanaway F, Mayanja HK, et al. Polypharmacy among HIV positive older adults on anti-retroviral therapy attending an urban clinic in Uganda. BMC Geriatr. 2018 May 29;18(1):125. PubMed PMID: 29843635; PubMed Central PMCID: PMC5975487.
   PubMed Web of Science ®Google Scholar
• Marzolini C, Back D, Weber R, et al. Ageing with HIV: medication use and risk for potential drug-drug interactions. J Antimicrob Chemother. 2011 Sep;66(9):2107–2111. PubMed PMID: 21680580.
   PubMed Web of Science ®Google Scholar
• Grant RW, Devita NG, Singer DE, et al. Polypharmacy and medication adherence in patients with type 2 diabetes. Diabetes Care. 2003 May;26(5):1408–1412. PubMed PMID: 12716797.
   PubMed Web of Science ®Google Scholar
• Monane M, Bohn RL, Gurwitz JH, et al. The effects of initial drug choice and comorbidity on antihypertensive therapy compliance: results from a population-based study in the elderly. Am J Hypertens. 1997 Jul;10(7 Pt 1):697–704. PubMed PMID: 9234822.
   PubMed Web of Science ®Google Scholar
• Salazar JA, Poon I, Nair M. Clinical consequences of polypharmacy in elderly: expect the unexpected, think the unthinkable. Expert Opin Drug Saf. 2007 Nov;6(6):695–704. PubMed PMID: 17967158.
   PubMed Web of Science ®Google Scholar
• Shalansky SJ, Levy AR. Effect of number of medications on cardiovascular therapy adherence. Ann Pharmacother. 2002 Oct;36(10):1532–1539. PubMed PMID: 12243601.
   PubMed Web of Science ®Google Scholar
• Kamal S, Bugnon O, Cavassini M, et al. HIV-infected patients’ beliefs about their chronic co-treatments in comparison with their combined antiretroviral therapy. HIV Med. 2018 Jan;19(1):49–58. PubMed PMID: 28815917; PubMed Central PMCID: PMC5724507.
   PubMed Web of Science ®Google Scholar
• Fried TR, O’Leary J, Towle V, et al. Health outcomes associated with polypharmacy in community-dwelling older adults: a systematic review. J Am Geriatr Soc. 2014 Dec;62(12):2261–2272. PubMed PMID: 25516023; PubMed Central PMCID: PMC4270076.
   PubMed Web of Science ®Google Scholar
• Pugh MJ, Palmer RF, Parchman ML, et al. Association of suboptimal prescribing and change in lower extremity physical function over time. Gerontology. 2007;53(6):445–453. PubMed PMID: 18309233.
   PubMed Web of Science ®Google Scholar
• Rawle MJ, Cooper R, Kuh D, et al. Associations between polypharmacy and cognitive and physical capability: a British Birth Cohort Study. J Am Geriatr Soc. 2018 May;66(5):916–923. PubMed PMID: 29574684; PubMed Central PMCID: PMC6001617.
   PubMed Web of Science ®Google Scholar
• Shah BM, Hajjar ER. Polypharmacy, adverse drug reactions, and geriatric syndromes. Clin Geriatr Med. 2012 May;28(2):173–186. PubMed PMID: 22500537.
   PubMed Web of Science ®Google Scholar
• Thai L, Young M The impact of number of medications on falls in aging persons living with HIV. 9th International Workshop on HIV & Aging; September 13–14; New York; 2018.
   Google Scholar
• Beers MH, Ouslander JG, Rollingher I, et al. Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA division of geriatric medicine. Arch Intern Med. 1991 Sep;151(9):1825–1832. PubMed PMID: 1888249.
   PubMedGoogle Scholar
• Gurwitz JH. Suboptimal medication use in the elderly. The tip of the iceberg. JAMA. 1994 Jul 27;272(4):316–317. PubMed PMID: 8028148.
   PubMed Web of Science ®Google Scholar
• Hanlon JT, Schmader KE, Ruby CM, et al. Suboptimal prescribing in older inpatients and outpatients. J Am Geriatr Soc. 2001 Feb;49(2):200–209. PubMed PMID: 11207875.
   PubMed Web of Science ®Google Scholar
• Hansen CR, Byrne S, Cullinan S, et al. Longitudinal patterns of potentially inappropriate prescribing in early old-aged people. Eur J Clin Pharmacol. 2018 Mar;74(3):307–313. PubMed PMID: 29177646.
   PubMed Web of Science ®Google Scholar
• Schmader K, Hanlon JT, Weinberger M, et al. Appropriateness of medication prescribing in ambulatory elderly patients. J Am Geriatr Soc. 1994 Dec;42(12):1241–1247. PubMed PMID: 7983285.
   PubMed Web of Science ®Google Scholar
• Dalleur O, Spinewine A, Henrard S, et al. Inappropriate prescribing and related hospital admissions in frail older persons according to the STOPP and START criteria. Drugs Aging. 2012 Oct;29(10):829–837. PubMed PMID: 23044639.
   PubMed Web of Science ®Google Scholar
• Hamilton H, Gallagher P, Ryan C, et al. Potentially inappropriate medications defined by STOPP criteria and the risk of adverse drug events in older hospitalized patients. Arch Intern Med. 2011 Jun 13;171(11):1013–1019. PubMed PMID: 21670370.
   PubMed Web of Science ®Google Scholar
• Hedna K, Hakkarainen KM, Gyllensten H, et al. Potentially inappropriate prescribing and adverse drug reactions in the elderly: a population-based study. Eur J Clin Pharmacol. 2015 Dec;71(12):1525–1533. PubMed PMID: 26407684; PubMed Central PMCID: PMC4643104.
   PubMed Web of Science ®Google Scholar
• Muhlack DC, Hoppe LK, Weberpals J, et al. The association of potentially inappropriate medication at older age with cardiovascular events and overall mortality: a systematic review and meta-analysis of cohort studies. J Am Med Dir Assoc. 2017 Mar 1;18(3):211–220. PubMed PMID: 28131719.
   PubMed Web of Science ®Google Scholar
• Reich O, Rosemann T, Rapold R, et al. Potentially inappropriate medication use in older patients in Swiss managed care plans: prevalence, determinants and association with hospitalization. PLoS One. 2014;9(8):e105425. PubMed PMID: 25136981; PubMed Central PMCID: PMC4138178.
   PubMed Web of Science ®Google Scholar
• Kaufmann CP, Tremp R, Hersberger KE, et al. Inappropriate prescribing: a systematic overview of published assessment tools. Eur J Clin Pharmacol. 2014 Jan;70(1):1–11. PubMed PMID: 24019054.
   PubMed Web of Science ®Google Scholar
• Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly. An update. Arch Intern Med. 1997 Jul 28;157(14):1531–1536. PubMed PMID: 9236554.
   PubMed Web of Science ®Google Scholar
• Gallagher P, Ryan C, Byrne S, et al. STOPP (Screening Tool of Older Person’s Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. Int J Clin Pharmacol Ther. 2008 Feb;46(2):72–83. PubMed PMID: 18218287.
   PubMed Web of Science ®Google Scholar
• Chang C-B, Chen J-H, Wen C-J, et al. Potentially inappropriate medications in geriatric outpatients with polypharmacy: application of six sets of published explicit criteria. Br J Clin Pharmacol. 2011 Sep;72(3):482–489. PubMed PMID: 21557760; PubMed Central PMCID: PMC3175518.
   PubMed Web of Science ®Google Scholar
• Desnoyer A, Guignard B, Lang P-O, et al. [Potentially inappropriate medications in geriatrics: which tools to detect them?]. Presse Med. 2016 Nov;45(11):957–970. PubMed PMID: 27633589.
   PubMed Web of Science ®Google Scholar
• Curtain CM, Bindoff IK, Westbury JL, et al. A comparison of prescribing criteria when applied to older community-based patients. Drugs Aging. 2013 Nov;30(11):935–943. PubMed PMID: 24002743.
   PubMed Web of Science ®Google Scholar
• O’Mahony D, Gallagher P, Ryan C, et al. STOPP & START criteria: a new approach to detecting potentially inappropriate prescribing in old age. Eur Geriatric Med. 2010;1:45–51.
   Web of Science ®Google Scholar
• Dalleur O, Boland B, Losseau C, et al. Reduction of potentially inappropriate medications using the STOPP criteria in frail older inpatients: a randomised controlled study. Drugs Aging. 2014 Apr;31(4):291–298. PubMed PMID: 24566877.
   PubMed Web of Science ®Google Scholar
• Frankenthal D, Lerman Y, Kalendaryev E, et al. Intervention with the screening tool of older persons potentially inappropriate prescriptions/screening tool to alert doctors to right treatment criteria in elderly residents of a chronic geriatric facility: a randomized clinical trial. J Am Geriatr Soc. 2014 Sep;62(9):1658–1665. PubMed PMID: 25243680.
   PubMed Web of Science ®Google Scholar
• Gallagher PF, O’Connor MN, O’Mahony D. Prevention of potentially inappropriate prescribing for elderly patients: a randomized controlled trial using STOPP/START criteria. Clin Pharmacol Ther. 2011 Jun;89(6):845–854. PubMed PMID: 21508941.
   PubMed Web of Science ®Google Scholar
• García-Gollarte F, Baleriola-Júlvez J, Ferrero-López I, et al. An educational intervention on drug use in nursing homes improves health outcomes resource utilization and reduces inappropriate drug prescription. J Am Med Dir Assoc. 2014 Dec;15(12):885–891. PubMed PMID: 24895001.
   PubMed Web of Science ®Google Scholar
• Hill-Taylor B, Walsh KA, Stewart S, et al. Effectiveness of the STOPP/START (Screening Tool of Older Persons’ Potentially Inappropriate Prescriptions/Screening Tool to Alert doctors to the Right Treatment) criteria: systematic review and meta-analysis of randomized controlled studies. J Clin Pharm Ther. 2016 Apr;41(2):158–169. PubMed PMID: 26990017.
   PubMed Web of Science ®Google Scholar
• Rudolph JL, Salow MJ, Angelini MC, et al. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med. 2008 Mar 10;168(5):508–513. PubMed PMID: 18332297.
   PubMedGoogle Scholar
• Rochon PA, Gurwitz JH. Drug therapy. Lancet. 1995 Jul 1;346(8966):32–36. PubMed PMID: 7603146.
   PubMed Web of Science ®Google Scholar
• Gill SS, Anderson GM, Fischer HD, et al. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Arch Intern Med. 2009 May 11;169(9):867–873. PubMed PMID: 19433698.
   PubMedGoogle Scholar
• Rochon PA, Gurwitz JH. The prescribing cascade revisited. Lancet. 2017 May 6;389(10081):1778–1780. PubMed PMID: 28495154.
   PubMed Web of Science ®Google Scholar
• Kalisch LM, Caughey GE, Roughead EE, et al. The prescribing cascade. Aust Prescr. 2011;34:162–166.
   Web of Science ®Google Scholar
• Kwan D, Farrell B. Polypharmacy: optimizing medication use in elderly patients. Can Geriatr Soc J Cont Med Educ. 2014;4:21–27.
   Google Scholar
• Rochon PA, Gurwitz JH. Optimising drug treatment for elderly people: the prescribing cascade. BMJ. 1997 Oct 25;315(7115):1096–1099. PubMed PMID: 9366745; PubMed Central PMCID: PMC2127690.
   PubMed Web of Science ®Google Scholar
• Caughey GE, Roughead EE, Pratt N, et al. Increased risk of hip fracture in the elderly associated with prochlorperazine: is a prescribing cascade contributing? Pharmacoepidemiol Drug Saf. 2010 Sep;19(9):977–982. PubMed PMID: 20623516.
   PubMed Web of Science ®Google Scholar
• Corrao G, Botteri E, Bagnardi V, et al. Generating signals of drug-adverse effects from prescription databases and application to the risk of arrhythmia associated with antibacterials. Pharmacoepidemiol Drug Saf. 2005 Jan;14(1):31–40. PubMed PMID: 15390219.
   PubMed Web of Science ®Google Scholar
• Gill SS, Mamdani M, Naglie G, et al. A prescribing cascade involving cholinesterase inhibitors and anticholinergic drugs. Arch Intern Med. 2005 Apr 11;165(7):808–813. PubMed PMID: 15824303.
   PubMedGoogle Scholar
• Gurwitz JH, Avorn J, Bohn RL, et al. Initiation of antihypertensive treatment during nonsteroidal anti-inflammatory drug therapy. JAMA. 1994 Sep 14;272(10):781–786. PubMed PMID: 8078142.
   PubMed Web of Science ®Google Scholar
• Liu PT, Argento VS, Skudlarska BA. Prescribing cascade in an 80-year-old Japanese immigrant. Geriatr Gerontol Int. 2009 Dec;9(4):402–404. PubMed PMID: 20002762.
   PubMed Web of Science ®Google Scholar
• Nguyen PV, Spinelli C. Prescribing cascade in an elderly woman. Can Pharm J (Ott). 2016 May;149(3):122–124. PubMed PMID: 27212961; PubMed Central PMCID: PMC4860747.
   PubMedGoogle Scholar
• Onder G, Bonassi S, Abbatecola AM, et al. High prevalence of poor quality drug prescribing in older individuals: a nationwide report from the Italian Medicines Agency (AIFA). J Gerontol A Biol Sci Med Sci. 2014 Apr;69(4):430–437. PubMed PMID: 23913935.
   PubMed Web of Science ®Google Scholar
• Rosenberg J, Rochon PA, Gill SS. Unveiling a prescribing cascade in an older man. J Am Geriatr Soc. 2014 Mar;62(3):580–581. PubMed PMID: 24628637.
   PubMed Web of Science ®Google Scholar
• Vegter S, de Jong-van Den Berg LT. Misdiagnosis and mistreatment of a common side-effect–angiotensin-converting enzyme inhibitor-induced cough. Br J Clin Pharmacol. 2010 Feb;69(2):200–203. PubMed PMID: 20233184; PubMed Central PMCID: PMC2824482.
   PubMed Web of Science ®Google Scholar
• Veloso TS, Cambao MS. Migraine treatment: a chain of adverse effects. Springerplus. 2015;4: 409. PubMed PMID: 26266080; PubMed Central PMCID: PMC4530541.
   PubMedGoogle Scholar
• Vouri SM, Chung JM, Binder EF. Successful intervention to mitigate an acetylcholinesterase inhibitor-induced rhinorrhea prescribing cascade: a case report. J Clin Pharm Ther. 2017 Jun;42(3):370–371. PubMed PMID: 28251653; PubMed Central PMCID: PMC5516898.
   PubMed Web of Science ®Google Scholar
• Hakkarainen KM, Hedna K, Petzold M, et al. Percentage of patients with preventable adverse drug reactions and preventability of adverse drug reactions–a meta-analysis. PLoS One. 2012;7(3): e33236. PubMed PMID: 22438900; PubMed Central PMCID: PMC3305295.
   PubMed Web of Science ®Google Scholar
• Aronson JK. Balanced prescribing - principles and challenges. Br J Clin Pharmacol. 2012 Oct;74(4):566–572. PubMed PMID: 22950551; PubMed Central PMCID: PMC3477323.
   PubMed Web of Science ®Google Scholar
• Brath H, Mehta N, Savage RD, et al. What is known about preventing, detecting, and reversing prescribing cascades: a scoping review. J Am Geriatr Soc. 2018 Nov;66(11):2079–2085. PubMed PMID: 30335185.
   PubMed Web of Science ®Google Scholar
• Ranzani A, Oreni L, Agro M, et al. Burden of exposure to potential interactions between antiretroviral and non-antiretroviral medications in a population of HIV-positive patients aged 50 years or older. J Acquir Immune Defic Syndr. 2018 Jun 1;78(2):193–201. PubMed PMID: 29767640.
   PubMed Web of Science ®Google Scholar
• Tseng A, Szadkowski L, Walmsley S, et al. Association of age with polypharmacy and risk of drug interactions with antiretroviral medications in HIV-positive patients. Ann Pharmacother. 2013 Nov;47(11):1429–1439. PubMed PMID: 24285760.
   PubMed Web of Science ®Google Scholar
• Marzolini C, Gibbons S, Khoo S, et al. Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications. J Antimicrob Chemother. 2016 Jul;71(7):1755–1758. PubMed PMID: 26945713.
   PubMed Web of Science ®Google Scholar
• Kumar P, Gordon LA, Brooks KM, et al. Differential influence of the antiretroviral pharmacokinetic enhancers ritonavir and cobicistat on intestinal P-glycoprotein transport and the pharmacokinetic/pharmacodynamic disposition of dabigatran. Antimicrob Agents Chemother. 2017 Nov;61. PubMed PMID: 28848011; PubMed Central PMCID: PMC5655101.
   Web of Science ®Google Scholar
• Zhu L, Persson A, Mahnke L, et al. Effect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects. J Clin Pharmacol. 2011 Mar;51(3):368–377. PubMed PMID: 20457590.
   PubMed Web of Science ®Google Scholar
• Crauwels H, van Heeswijk RP, Stevens M, et al. Clinical perspective on drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor rilpivirine. AIDS Rev. 2013 Apr;15(2):87–101. PubMed PMID: 23681436 [Jun].
   PubMed Web of Science ®Google Scholar
• Kiser JJ, Bumpass JB, Meditz AL, et al. Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers. Antimicrob Agents Chemother. 2010 Dec;54(12):4999–5003. PubMed PMID: 20921313; PubMed Central PMCID: PMC2981249.
   PubMed Web of Science ®Google Scholar
• Ramanathan S, Mathias A, Wei X, et al. Pharmacokinetics of once-daily boosted elvitegravir when administered in combination with acid-reducing agents. J Acquir Immune Defic Syndr. 2013 Sep 1;64(1):45–50. PubMed PMID: 23774876.
   PubMed Web of Science ®Google Scholar
• Song I, Borland J, Arya N, et al. Pharmacokinetics of dolutegravir when administered with mineral supplements in healthy adult subjects. J Clin Pharmacol. 2015 May;55(5):490–496. PubMed PMID: 25449994; PubMed Central PMCID: PMC4407950.
   PubMed Web of Science ®Google Scholar
• Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/AIDS. Nat Rev Drug Discov. 2005 Mar;4(3):236–248. PubMed PMID: 15729361.
   PubMed Web of Science ®Google Scholar
• Chauvin B, Drouot S, Barrail-Tran A, et al. Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. Clin Pharmacokinet. 2013 Oct;52(10):815–831. PubMed PMID: 23703578.
   PubMed Web of Science ®Google Scholar
• Song IH, Zong J, Borland J, et al. The effect of dolutegravir on the pharmacokinetics of metformin in healthy subjects. J Acquir Immune Defic Syndr. 2016 Aug 1;72(4):400–407. PubMed PMID: 26974526; PubMed Central PMCID: PMC4935531.
   PubMed Web of Science ®Google Scholar
• Zhang H, West SK, Vu A, et al. Lack of clinically relevant effect of bictegravir on metformin pharmacokinetics and pharmacodynamics. 18th International Workshop on Clinical Pharmacology of Antiviral Therapy; June 14–16; Chicago; 2017.
   Google Scholar
• Gupta SK, Anderson AM, Ebrahimi R, et al. Fanconi syndrome accompanied by renal function decline with tenofovir disoproxil fumarate: a prospective, case-control study of predictors and resolution in HIV-infected patients. PLoS One. 2014;9(3):e92717. PubMed PMID: 24651857; PubMed Central PMCID: PMC3961428.
   PubMed Web of Science ®Google Scholar
• Psevdos G Jr., Gonzalez E, Sharp V. Acute renal failure in patients with AIDS on tenofovir while receiving prolonged vancomycin course for osteomyelitis. AIDS Read. 2009 Jun Jul; 19(6):245–248. PubMed PMID: 19642243.
   PubMedGoogle Scholar
• Ray AS, Fordyce MW, Hitchcock MJ. Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus. PubMed PMID: 26640223. Antiviral Res. 2016 Jan;125:63–70
   PubMed Web of Science ®Google Scholar
• Liverpool HIV drug interactions website. [Cited 2019 Jan 15]. Available from: http://www.hiv-druginteractions.org
   Google Scholar
• Toronto general hospital immunodeficiency clinic’s drug therapy guide. [Cited 2019 Jan 15]. Available from: http://app.hivclinic.ca
   Google Scholar
• University of California HIVInSite website. [Cited 2019 Jan 15]. Available from: http://hivinsite.ucsf.edu
   Google Scholar
• Micromedex. [Cited 2019 Jan 15]. Available from: http://www.micromedexsolutions.com
   Google Scholar
• Lexicomp. [Cited 2019 Jan 15]. Available from: http://online.lexi.com/lco/action.home
   Google Scholar
• Krishna R, East L, Larson P, et al. Effect of metal-cation antacids on the pharmacokinetics of 1200 mg raltegravir. J Pharm Pharmacol. 2016 Nov;68(11):1359–1365. PubMed PMID: 27671833.
   PubMed Web of Science ®Google Scholar
• Elliot ER, Theodoraki A, Jain LR, et al. Iatrogenic Cushing’s syndrome due to drug interaction between glucocorticoids and the ritonavir or cobicistat containing HIV therapies. Clin Med (Lond). 2016 Oct;16(5):412–418. PubMed PMID: 27697800.
   PubMed Web of Science ®Google Scholar
• Saberi P, Phengrasamy T, Nguyen DP. Inhaled corticosteroid use in HIV-positive individuals taking protease inhibitors: a review of pharmacokinetics, case reports and clinical management. HIV Med. 2013 Oct;14(9):519–529. PubMed PMID: 23590676; PubMed Central PMCID: PMC3758391.
   PubMed Web of Science ®Google Scholar
• Siccardi M, Marzolini C, Seden K, et al. Prediction of drug-drug interactions between various antidepressants and efavirenz or boosted protease inhibitors using a physiologically based pharmacokinetic modelling approach. Clin Pharmacokinet. 2013 Jul;52(7):583–592. PubMed PMID: 23479398.
   PubMed Web of Science ®Google Scholar
• Fulco PP, Zingone MM, Higginson RT. Possible antiretroviral therapy-warfarin drug interaction. Pharmacotherapy. 2008 Jul;28(7):945–949. PubMed PMID: 18576910.
   PubMed Web of Science ®Google Scholar
• Good BL, Gomes DC, Fulco PP. An unexpected interaction between warfarin and cobicistat-boosted elvitegravir. Aids. 2015 May 15;29(8):985–986. PubMed PMID: 25909832.
   PubMed Web of Science ®Google Scholar
• Hughes CA, Freitas A, Miedzinski LJ. Interaction between lopinavir/ritonavir and warfarin. Cmaj. 2007 Aug 14;177(4):357–359. PubMed PMID: 17698824; PubMed Central PMCID: PMC1942099.
   PubMed Web of Science ®Google Scholar
• Tseng AL, Luetkehoelter J, Walmsley SL. Increase in international normalized ratio after switching from atazanavir/ritonavir to darunavir/cobicistat in a patient on warfarin: boosters are not always equal. Aids. 2017 Jan 2;31(1):175–176. PubMed PMID: 27898595.
   PubMed Web of Science ®Google Scholar
• Welzen ME, van Den Berk GE, Hamers RL, et al. Interaction between antiretroviral drugs and acenocoumarol. Antivir Ther. 2011;16(2): 249–252. PubMed PMID: 21447874.
   PubMed Web of Science ®Google Scholar
• Corallo CE, Grannell L, Tran H. Postoperative bleeding after administration of a single dose of rivaroxaban to a patient receiving antiretroviral therapy. Drug Saf Case Rep. 2015 Dec;2(1):11. PubMed PMID: 27747723; PubMed Central PMCID: PMC5005638.
   PubMedGoogle Scholar
• Lakatos B, Stoeckle M, Elzi L, et al. Gastrointestinal bleeding associated with rivaroxaban administration in a treated patient infected with human immunodeficiency virus. Swiss Med Wkly. 2014 Jan;22(144):w13906. PubMed PMID: 24452338.
   Google Scholar
• Yoong D, Naccarato M, Gough K. Extensive bruising and elevated rivaroxaban plasma concentration in a patient receiving cobicistat-boosted elvitegravir. Ann Pharmacother. 2017 Aug;51(8):713–714. PubMed PMID: 28351160.
   PubMed Web of Science ®Google Scholar
• Bravo I, Alvarez H, Marino A, et al. Recurrent coronary disease in HIV-infected patients: role of drug-drug interactions. Br J Clin Pharmacol. 2018 Jul;84(7):1617–1619. PubMed PMID: 29663482; PubMed Central PMCID: PMC6005598.
   PubMed Web of Science ®Google Scholar
• Itkonen MK, Tornio A, Lapatto-Reiniluoto O, et al. Clopidogrel increases dasabuvir exposure with or without ritonavir, and ritonavir inhibits the bioactivation of clopidogrel. Clin Pharmacol Ther. 2019 Jan;105(1):219–228. PubMed PMID: 29696643.
   Web of Science ®Google Scholar
• Marsousi N, Daali Y, Fontana P, et al. Impact of boosted antiretroviral therapy on the pharmacokinetics and efficacy of clopidogrel and prasugrel active metabolites. Clin Pharmacokinet. 2018 Oct;57(10):1347–1354. PubMed PMID: 29453687.
   PubMed Web of Science ®Google Scholar
• Busti AJ, Tsikouris JP, Peeters MJ, et al. A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV-positive patients. HIV Med. 2006 7;Jul(5):317–322. PubMed PMID: 16945077.
   Web of Science ®Google Scholar
• Glesby MJ, Aberg JA, Kendall MA, et al. Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockers. Clin Pharmacol Ther. 2005 Aug;78(2):143–153. PubMed PMID: 16084849.
   PubMed Web of Science ®Google Scholar
• Mukherjee D, Zha J, Menon RM, et al. Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model. J Pharmacokinet Pharmacodyn. 2018 Jun;45(3):443–446. PubMed PMID: 29427135; PubMed Central PMCID: PMC5953987.
   PubMed Web of Science ®Google Scholar
• Malvestutto CD, Ma Q, Morse GD, et al. Lack of pharmacokinetic interactions between pitavastatin and efavirenz or darunavir/ritonavir. J Acquir Immune Defic Syndr. 2014 Dec 1;67(4):390–396. PubMed PMID: 25202920; PubMed Central PMCID: PMC4404408.
   PubMed Web of Science ®Google Scholar
• Berretta M, Caraglia M, Martellotta F, et al. Drug-drug interactions based on pharmacogenetic profile between highly active antiretroviral therapy and antiblastic chemotherapy in cancer patients with HIV infection. Front Pharmacol. 2016;7:71, PubMed PMID: 27065862; PubMed Central PMCID: PMC4811911
   PubMed Web of Science ®Google Scholar
• Chary A, Nguyen NN, Maiton K, et al. A review of drug-drug interactions in older HIV-infected patients. Expert Rev Clin Pharmacol. 2017 Dec;10(12):1329–1352. PubMed PMID: 28922979.
   PubMed Web of Science ®Google Scholar
• Spano JP, Poizot-Martin I, Costagliola D, et al. Non-AIDS-related malignancies: expert consensus review and practical applications from the multidisciplinary CANCERVIH Working Group. Ann Oncol. 2016 Mar;27(3):397–408. PubMed PMID: 26681686.
   PubMed Web of Science ®Google Scholar
• Garraffo R, Lavrut T, Ferrando S, et al. Effect of tipranavir/ritonavir combination on the pharmacokinetics of tadalafil in healthy volunteers. J Clin Pharmacol. 2011 Jul;51(7):1071–1078. PubMed PMID: 21209236.
   PubMed Web of Science ®Google Scholar
• Muirhead GJ, Wulff MB, Fielding A, et al. Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Br J Clin Pharmacol. 2000 Aug;50(2):99–107. PubMed PMID: 10930961; PubMed Central PMCID: PMC2014393.
   PubMed Web of Science ®Google Scholar
• Kreutzwiser D, Tseng A. Drug interactions between antiretrovirals and drugs used to treat benign prostatic hyperplasia/lower urinary tract symptoms. Expert Opin Drug Metab Toxicol. 2016 Oct;12(10):1211–1224. PubMed PMID: 27376653.
   PubMed Web of Science ®Google Scholar
• Bickel M, Khaykin P, Stephan C, et al. Acute kidney injury caused by tenofovir disoproxil fumarate and diclofenac co-administration. HIV Med. 2013 Nov;14(10):633–638. PubMed PMID: 23980564.
   PubMed Web of Science ®Google Scholar
• Dooley KE, Sayre P, Borland J, et al. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr. 2013 Jan 1;62(1):21–27. PubMed PMID: 23075918.
   PubMed Web of Science ®Google Scholar
• Taburet AM, Sauvageon H, Grinsztejn B, et al. Pharmacokinetics of raltegravir in HIV-infected patients on rifampicin-based antitubercular therapy. Clin Infect Dis. 2015 Oct 15;61(8):1328–1335. PubMed PMID: 26105170.
   PubMed Web of Science ®Google Scholar
• Atwine D, Bonnet M, Taburet AM. Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high human immunodeficiency virus and tuberculosis burden countries: a systematic review. Br J Clin Pharmacol. 2018 Aug;84(8):1641–1658. PubMed PMID: 29624706; PubMed Central PMCID: PMC6046471.
   PubMed Web of Science ®Google Scholar
• Stader F, Kinvig H, Battegay M, et al. Analysis of clinical drug-drug interaction data to predict magnitudes of uncharacterized interactions between antiretroviral drugs and comedications. Antimicrob Agents Chemother. 2018 Jul;62(7):e00717–18. PubMed PMID: 29686151; PubMed Central PMCID: PMC6021627.
   PubMed Web of Science ®Google Scholar
• Fromm MF, Dilger K, Busse D, et al. Gut wall metabolism of verapamil in older people: effects of rifampicin-mediated enzyme induction. Br J Clin Pharmacol. 1998 Mar;45(3):247–255. PubMed PMID: 9517368; PubMed Central PMCID: PMC1873368.
   PubMed Web of Science ®Google Scholar
• Lorgunpai SJ, Grammas M, Lee DS, et al. Potential therapeutic competition in community-living older adults in the U.S.: use of medications that may adversely affect a coexisting condition. PLoS One. 2014;9(2): e89447. PubMed PMID: 24586786; PubMed Central PMCID: PMC3934884.
   PubMed Web of Science ®Google Scholar
• Penfornis A, Kury-Paulin S. Immunosuppressive drug-induced diabetes. Diabetes Metab. 2006 Dec;32(5 Pt 2):539–546. PubMed PMID: 17130815.
   PubMed Web of Science ®Google Scholar
• Casado JL, Santiuste C, Vazquez M, et al. Bone mineral density decline according to renal tubular dysfunction and phosphaturia in tenofovir-exposed HIV-infected patients. Aids. 2016 Jun 1;30(9):1423–1431. PubMed PMID: 26919733.
   PubMed Web of Science ®Google Scholar
• Dorjee K, Baxi SM, Reingold AL, et al. Risk of cardiovascular events from current, recent, and cumulative exposure to abacavir among persons living with HIV who were receiving antiretroviral therapy in the United States: a cohort study. BMC Infect Dis. 2017 Oct 27;17(1):708. PubMed PMID: 29078761; PubMed Central PMCID: PMC5660446.
   PubMed Web of Science ®Google Scholar
• Nozza S, Malagoli A, Maia L, et al. Antiretroviral therapy in geriatric HIV patients: the GEPPO cohort study. J Antimicrob Chemother. 2017 Oct 1;72(10):2879–2886. PubMed PMID: 28605493.
   PubMed Web of Science ®Google Scholar
• Edelman EJ, Gordon KS, Glover J, et al. The next therapeutic challenge in HIV: polypharmacy. Drugs Aging. 2013 Aug;30(8):613–628. PubMed PMID: 23740523; PubMed Central PMCID: PMC3715685.
   PubMed Web of Science ®Google Scholar
• Boyd CM, Darer J, Boult C, et al. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA. 2005 Aug 10;294(6):716–724. PubMed PMID: 16091574.
   PubMed Web of Science ®Google Scholar
• Tinetti ME, Bogardus ST Jr., Agostini JV. Potential pitfalls of disease-specific guidelines for patients with multiple conditions. N Engl J Med. 2004 Dec 30;351(27):2870–2874. PubMed PMID: 15625341.
   PubMed Web of Science ®Google Scholar
• Boyd CM, Lucas GM. Patient-centered care for people living with multimorbidity. Curr Opin HIV AIDS. 2014 Jul;9(4):419–427. PubMed PMID: 24871089; PubMed Central PMCID: PMC4144702.
   PubMed Web of Science ®Google Scholar
• Martin P, Tamblyn R, Benedetti A, et al. Effect of a pharmacist-led educational intervention on inappropriate medication prescriptions in older adults: the D-PRESCRIBE randomized clinical trial. JAMA. 2018 Nov 13;320(18):1889–1898. PubMed PMID: 30422193; PubMed Central PMCID: PMC6248132.
   PubMed Web of Science ®Google Scholar
• Scott IA, Hilmer SN, Reeve E, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015 May;175(5):827–834. PubMed PMID: 25798731.
   PubMed Web of Science ®Google Scholar
• Medstopper. [Cited 2019 Jan 15]. Available from: http://medstopper.com
   Google Scholar
• Deprescribing. [Cited 2019 Jan 15]. Available from: http://deprescribing.org
   Google Scholar
• Drenth-van Maanen AC, Leendertse AJ, Jansen PAF, et al. The systematic tool to reduce inappropriate prescribing (STRIP): combining implicit and explicit prescribing tools to improve appropriate prescribing. J Eval Clin Pract. 2018 Apr;24(2):317–322. PubMed PMID: 28776873.
   PubMed Web of Science ®Google Scholar
• Soiza RL, Subbarayan S, Antonio C, et al. The SENATOR project: developing and trialling a novel software engine to optimize medications and nonpharmacological therapy in older people with multimorbidity and polypharmacy. Ther Adv Drug Saf. 2017 Mar;8(3):81–85. PubMed PMID: 28382196; PubMed Central PMCID: PMC5367661.
   PubMed Web of Science ®Google Scholar